Satellos Bioscience Inc. (MSLE) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 1, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Mar 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MSLE SEC filings page.
This page shows Satellos Bioscience Inc. (MSLE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Satellos Bioscience Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Satellos Bioscience Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Satellos Bioscience Inc. reported a net loss of $24.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Satellos Bioscience Inc. held $9.8M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
MSLE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
MSLE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'2410-K | Q4'2310-K |
|---|---|---|---|
| Total Assets | $31.9M-37.2% | $50.7M+51.5% | $33.5M |
| Current Assets | $31.9M-37.2% | $50.7M+66.5% | $30.5M |
| Cash & Equivalents | $9.8M-75.5% | $40.1M+140.2% | $16.7M |
| Total Liabilities | $4.1M+14.6% | $3.6M+31.1% | $2.7M |
| Current Liabilities | $4.1M+14.6% | $3.6M+31.1% | $2.7M |
| Non-Current Liabilities | $0 | $0 | $0 |
| Total Equity | $27.8M-41.1% | $47.2M+53.3% | $30.8M |
| Retained Earnings | -$82.0M-43.6% | -$57.1M-56.6% | -$36.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
MSLE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
MSLE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Where Satellos Bioscience Inc. Ranks
Frequently Asked Questions
Is Satellos Bioscience Inc. profitable?
No, Satellos Bioscience Inc. (MSLE) reported a net income of -$24.9M in fiscal year 2025.
What is Satellos Bioscience Inc.'s return on equity (ROE)?
Satellos Bioscience Inc. (MSLE) has a return on equity of -89.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Satellos Bioscience Inc.'s free cash flow?
Satellos Bioscience Inc. (MSLE) recorded an outflow of $23.6M in free cash flow during fiscal year 2025. This represents a -29.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Satellos Bioscience Inc.'s operating cash flow?
Satellos Bioscience Inc. (MSLE) recorded an outflow of $23.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Satellos Bioscience Inc.'s total assets?
Satellos Bioscience Inc. (MSLE) had $31.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Satellos Bioscience Inc.'s capital expenditures?
Satellos Bioscience Inc. (MSLE) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Satellos Bioscience Inc.'s current ratio?
Satellos Bioscience Inc. (MSLE) had a current ratio of 7.77 as of fiscal year 2025, which is generally considered healthy.
What is Satellos Bioscience Inc.'s debt-to-equity ratio?
Satellos Bioscience Inc. (MSLE) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Satellos Bioscience Inc.'s return on assets (ROA)?
Satellos Bioscience Inc. (MSLE) had a return on assets of -78.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Satellos Bioscience Inc.'s P/E ratio?
Satellos Bioscience Inc. (MSLE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $180.3M as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Satellos Bioscience Inc.'s price-to-sales ratio?
Satellos Bioscience Inc. (MSLE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $180.3M as of Oct 1, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Satellos Bioscience Inc.'s Piotroski F-Score?
Satellos Bioscience Inc. (MSLE) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Satellos Bioscience Inc.'s earnings high quality?
Satellos Bioscience Inc. (MSLE) reported a net loss of $24.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.